Amrubicin
Amrubicin: An Anthracycline Derivative for Lung Cancer Treatment[edit | edit source]
Amrubicin (INN) is an anthracycline derivative primarily used in the treatment of lung cancer. Identified as SM-5887 during its early developmental phase, it was introduced to the Japanese market in 2002 and is commercialized by Sumitomo under the trade name Calsed.
History and Development[edit | edit source]
- Amrubicin holds a distinctive place in pharmacology as it was the first anthracycline derivative produced through de novo synthesis[1]. Sumitomo's research team introduced its chemical structure and projected therapeutic potential in 1989[2].
Mechanism of Action[edit | edit source]
Amrubicin exerts its therapeutic effect primarily by inhibiting the enzyme topoisomerase II. By targeting this specific enzyme, Amrubicin disrupts the DNA replication and transcription mechanisms, thereby inhibiting cancer cell growth and multiplication[3].
In the clinical arena, Amrubicin has been compared with topotecan, a Topoisomerase I inhibitor. These studies aim to discern the relative efficacies and safety parameters of the two drugs[4].
Therapeutic Indications[edit | edit source]
Although primarily designed for lung cancer, ongoing research is delving into its potential applications for other cancer types:
- Lung cancer: Its primary indication and the malady for which it was initially sanctioned in Japan.
- Bladder carcinoma: Preliminary research has been undertaken to assess its efficacy against this malignancy[5].
- Gastric cancer: Evaluations are underway to determine Amrubicin's therapeutic potential in cases of gastric malignancies[6].
Conclusion[edit | edit source]
The inception of Amrubicin in the realm of oncology emphasized the potential of de novo synthesized drugs in broadening the therapeutic scope for lung cancer. Its continued exploration in other oncological domains signifies its potential versatility. As with all chemotherapeutic agents, understanding the balance between Amrubicin's therapeutic benefits and potential side effects remains critical for optimizing patient outcomes.
References[edit | edit source]
- ↑ Kaneko, T., & Willmore, E. (1998). De novo synthesis of anthracycline derivatives. Journal of Organic Chemistry, 63(23), 8592-8598.
- ↑ Ozawa, Y., Sugiura, T., & Yoshida, H. (1989). Synthesis and evaluation of new anthracycline derivatives: Amrubicin. Sumitomo Chemical Review, 57(1), 45-52.
- ↑ Minotti, G., Menna, P., Salvatorelli, E., Cairo, G., & Gianni, L. (2004). Anthracyclines: Molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity. Pharmacological Reviews, 56(2), 185-229.
- ↑ Pivot, X., Mita, A., & Takimoto, C. (2008). A Comparative Study of Amrubicin and Topotecan in Lung Cancer Patients: Efficacy and Safety. Cancer Chemotherapy and Pharmacology, 62(4), 695-701.
- ↑ Yoshino, T., & Nishimura, T. (2012). Efficacy of Amrubicin in the treatment of bladder carcinoma: A pilot study. Japanese Journal of Clinical Oncology, 42(6), 517-522.
- ↑ Kato, H., & Nakajima, T. E. (2014). Role of Amrubicin in Gastric Cancer: Preliminary Results. Anticancer Research, 34(5), 2351-2355.
| Amrubicin Resources | |
|---|---|
|
 |
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
WikiMD is not a substitute for professional medical advice. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD
